NRx Pharmaceuticals, Inc. Logo

NRx Pharmaceuticals, Inc.

NRXP

(1.8)
Stock Price

1,50 USD

-471.49% ROA

127.35% ROE

-0.63x PER

Market Cap.

15.909.260,00 USD

-46.73% DER

0% Yield

-254750% NPM

NRx Pharmaceuticals, Inc. Stock Analysis

NRx Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

NRx Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-8.07x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (-452%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

4 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

5 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

6 ROE

Negative ROE (-684.51%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

7 ROA

The stock's ROA (-182.27%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

NRx Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

NRx Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

NRx Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

NRx Pharmaceuticals, Inc. Revenue
Year Revenue Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

NRx Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2017 0
2018 0 0%
2019 3.496 100%
2020 10.625.000 99.97%
2021 20.257.000 47.55%
2022 17.027.000 -18.97%
2023 13.256.000 -28.45%
2023 13.371.000 0.86%
2024 11.216.000 -19.21%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

NRx Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 0
2018 0 0%
2019 2.768 100%
2020 11.436.000 99.98%
2021 74.944.000 84.74%
2022 27.370.000 -173.82%
2023 9.976.000 -174.36%
2023 14.216.000 29.83%
2024 16.984.000 16.3%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

NRx Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
2017 52.516
2018 -1.006.500 105.22%
2019 -6.262 -15973.14%
2020 -51.385.000 99.99%
2021 -115.794.000 55.62%
2022 -44.653.000 -159.32%
2023 -22.748.000 -96.29%
2023 -27.582.000 17.53%
2024 -28.196.000 2.18%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

NRx Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
2017 0
2018 -1.006.503 100%
2019 0 0%
2020 -907.406 100%
2021 -2.000 -45270.3%
2022 -4.000 50%
2023 0 0%
2023 -5.000 100%
2024 -4.000 -25%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

NRx Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
2017 -105.033
2018 66.101 258.9%
2019 408.427 83.82%
2020 -12.347.000 103.31%
2021 -71.715.000 82.78%
2022 -35.235.000 -103.53%
2023 -24.248.000 -45.31%
2023 -30.150.000 19.58%
2024 -31.588.000 4.55%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

NRx Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 0
2018 0 0%
2019 1 0%
2020 0 0%
2021 -2 100%
2022 -1 0%
2023 0 0%
2023 -4 100%
2024 -3 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

NRx Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
2017 -135.807
2018 -473.187 71.3%
2019 -792.735 40.31%
2020 -2.267.000 65.03%
2021 -37.710.000 93.99%
2022 -39.765.000 5.17%
2023 -21.660.000 -83.59%
2023 -4.566.000 -374.38%
2024 -3.505.000 -30.27%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

NRx Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
2017 -135.807
2018 -473.187 71.3%
2019 -792.731 40.31%
2020 -2.265.000 65%
2021 -37.703.000 93.99%
2022 -39.755.000 5.16%
2023 -21.657.000 -83.57%
2023 -4.564.000 -374.52%
2024 -3.505.000 -30.21%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

NRx Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
2017 0
2018 0 0%
2019 4 100%
2020 2.000 99.85%
2021 7.000 71.43%
2022 10.000 30%
2023 3.000 -233.33%
2023 2.000 -50%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

NRx Pharmaceuticals, Inc. Equity
Year Equity Growth
2017 69.472.648
2018 69.538.749 0.1%
2019 29.500.489 -135.72%
2020 -43.771.000 167.4%
2021 20.806.000 310.38%
2022 7.409.000 -180.82%
2023 -6.217.000 219.17%
2023 -11.733.000 47.01%
2024 -18.391.000 36.2%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

NRx Pharmaceuticals, Inc. Assets
Year Assets Growth
2017 69.565.819
2018 70.796.159 1.74%
2019 32.074.694 -120.72%
2020 2.941.000 -990.61%
2021 32.729.000 91.01%
2022 25.816.000 -26.78%
2023 13.110.000 -96.92%
2023 7.315.000 -79.22%
2024 5.264.000 -38.96%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

NRx Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
2017 93.171
2018 1.257.410 92.59%
2019 2.574.205 51.15%
2020 46.712.000 94.49%
2021 11.923.000 -291.78%
2022 18.407.000 35.23%
2023 19.327.000 4.76%
2023 19.048.000 -1.46%
2024 23.655.000 19.48%

NRx Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-2.36
Price to Earning Ratio
-0.63x
Price To Sales Ratio
1988.66x
POCF Ratio
-1.04
PFCF Ratio
-1.07
Price to Book Ratio
-0.85
EV to Sales
2825.66
EV Over EBITDA
-0.98
EV to Operating CashFlow
-1.51
EV to FreeCashFlow
-1.51
Earnings Yield
-1.59
FreeCashFlow Yield
-0.94
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
9.64
Graham NetNet
-2.07

Income Statement Metrics

Net Income per Share
-2.36
Income Quality
0.6
ROE
1.93
Return On Assets
-4.57
Return On Capital Employed
1.29
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-2559.5
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
1607.75
Research & Developement to Revenue
1300
Stock Based Compensation to Revenue
-64.13
Gross Profit Margin
0.63
Operating Profit Margin
-2559.5
Pretax Profit Margin
-2547.5
Net Profit Margin
-2547.5

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.42
Free CashFlow per Share
-1.42
Capex to Operating CashFlow
-0
Capex to Revenue
0.25
Capex to Depreciation
0.4
Return on Invested Capital
2.24
Return on Tangible Assets
-4.71
Days Sales Outstanding
273.75
Days Payables Outstanding
366095
Days of Inventory on Hand
0
Receivables Turnover
1.33
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,18
Book Value per Share
-1,75
Tangible Book Value per Share
-1.75
Shareholders Equity per Share
-1.75
Interest Debt per Share
0.85
Debt to Equity
-0.47
Debt to Assets
1.63
Net Debt to EBITDA
-0.29
Current Ratio
0.21
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-18775000
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
0
Debt to Market Cap
0.54

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

NRx Pharmaceuticals, Inc. Dividends
Year Dividends Growth

NRx Pharmaceuticals, Inc. Profile

About NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

CEO
Dr. Jonathan C. Javitt M.D., M
Employee
2
Address
1201 Orange Street
Wilmington, 19801

NRx Pharmaceuticals, Inc. Executives & BODs

NRx Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Mr. Richard Clavano Narido
Chief Financial Officer & Treasurer
70
2 Suzanne Messere
Investor Relations
70
3 Dr. Philip T. Lavin Ph.D.
Chief Methodologist
70
4 Mr. Matthew Patrick Duffy
Chief Business Officer & Co-Chief Executive Officer of Hope Therapeutics
70
5 Dr. Jonathan C. Javitt M.D., M.P.H.
Co-Founder, Chief Scientist Officer, Chairman & Interim Chief Executive Officer
70
6 Dr. Riccardo Panicucci Ph.D.
Chief Manufacturing & Technology Officer
70

NRx Pharmaceuticals, Inc. Competitors